Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.

Background: Levels of bone turnover markers (BTM) might be correlated with outcome in terms of skeletal-related events (SRE), disease progression, and death in patients with bladder cancer (BC) and renal cell carcinoma (RCC) with bone metastases (BM). We try to evaluate this possible correlation in patients who receive treatment with zoledronic acid (ZOL).

Methods: This observational, prospective, and multicenter study analysed BTM and clinical outcome in these patients.

Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.

Background: Owing to the limited validity of clinical data on the treatment of prostate cancer (PCa) and bone metastases, biochemical markers are a promising tool for predicting survival, disease progression and skeletal-related events (SREs) in these patients. The aim of this study was to evaluate the predictive capacity of biochemical markers of bone turnover for mortality risk, disease progression and SREs in patients with PCa and bone metastases undergoing treatment with zoledronic acid (ZA).

Methods: This was an observational, prospective and multicenter study in which ninety-eight patients were included.

Statistical shape and texture model of quadrature phase information for prostate segmentation.

Purpose: Prostate volume estimation from segmentation of transrectal ultrasound (TRUS) images aids in diagnosis and treatment of prostate hypertrophy and cancer. Computer-aided accurate and computationally efficient prostate segmentation in TRUS images is a challenging task, owing to low signal-to-noise ratio, speckle noise, calcifications, and heterogeneous intensity distribution in the prostate region.

Method: A multi-resolution framework using texture features in a parametric deformable statistical model of shape and appearance was developed to segment the prostate.

[Localization of prostate cancer within the central gland by endorectal MR spectroscopic imaging].

Objectives: The endorectal MR spectroscopic imaging is a new imaging test which allows more accurate and reliable localization and staging of prostate cancer than simple endorectal MRI. The combination of spectroscopic MR and MRI has recently achieved technical improvements that increased reliability in the detection of prostate cancer. Our group is now working in the detection of prostate cancer with the spectroscopic MR, in co-operation with the Agency for the Evaluation of Technology for Medical Research (Agencia de Evaluación de Tecnología para la Investigación Médica-AATRM); although we are waiting for definitive results, we can advance that this technique may be used as a good alternative for localization of prostate cancer in patients with previous negative biopsies in whom the suspicion of prostate cancer persists.